Browse

The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.

The appeal is the latest twist in the closely watched lawsuit filed by the American Association of Pediatrics.

At Wednesday's argument, the justices did not appear to question whether skinny labeling is valid.